Genedrive file US FDA Pre-Submission for the Genedrive ® MT-RNR1 Product Range
ValiRx PLC (AIM:VAL) Live Shareholder Q&A and industry events
Live Q&A: London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, invites shareholders to join the CEO, Suzy Dilly and
Genedrive PLC (AIM:GDR) NICE includes Genedrive CYP2C19-ID Kit in new Diagnostics Assessment Programme
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (‘NICE’) has commenced an evaluation of CYP2C19 genotype testing for
ValiRx PLC (AIM:VAL) Successful evaluation of breast cancer programme
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce that the project subject to the Evaluation
ValiRx PLC (AIM:VAL) Update on VAL201 sub-license agreement
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today providing an update on its proposed sub-license agreement with
Genedrive PLC (AIM:GDR) Point-of-Care COV19-ID Kit receives CTDA approval
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK Medicines and Healthcare Products Regulatory Agency has granted a CTDA enabling the sale of the Genedrive®
Genedrive PLC (AIM:GDR) NICE issues Medtech Innovation Briefing
NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test
Genedrive® MT-RNR1 ID Kit Product – Video
World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss
ValiRx PLC (AIM:VAL) Update on proposed sub-license of VAL201
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health today provides an update on progress towards the completion of the
Genedrive PLC (AIM:GDR) First NHS Deployments of Genedrive System for AIHL
First NHS Deployments of the Genedrive® System for Antibiotic Induced Hearing Loss
ValiRx PLC (AIM:VAL) Operational and Strategy Update
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today provides an update on operational activities and strategy.
